Literature DB >> 22951975

Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma.

Jeffrey K Mito1, Hooney D Min, Yan Ma, Jessica E Carter, Brian E Brigman, Leslie Dodd, David Dankort, Martin McMahon, David G Kirsch.   

Abstract

Undifferentiated pleomorphic sarcoma (UPS) is one of the most common soft tissue malignancies. Patients with large, high-grade sarcomas often develop fatal lung metastases. Understanding the mechanisms underlying sarcoma metastasis is needed to improve treatment of these patients. Micro-RNAs (miRNAs) are a class of small RNAs that post-transcriptionally regulate gene expression. Global alterations in miRNAs are frequently observed in a number of disease states including cancer. The signalling pathways that regulate miRNA biogenesis are beginning to emerge. To test the relevance of specific oncogenic mutations in miRNA biogenesis in sarcoma, we used primary soft tissue sarcomas expressing either Braf(V600E) or Kras(G12D). We found that Braf(V600E) mutant tumours, which have increased MAPK signalling, have higher levels of mature miRNAs and enhanced miRNA processing. To investigate the relevance of oncogene-dependent alterations in miRNA biogenesis, we introduced conditional mutations in Dicer and showed that Dicer haploinsufficiency promotes the development of distant metastases in an oncogene-dependent manner. These results demonstrate that a specific oncogenic mutation can cooperate with mutation in Dicer to promote tumour progression in vivo.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951975      PMCID: PMC3552559          DOI: 10.1002/path.4099

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  40 in total

1.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

Review 2.  Non-coding RNAs in human disease.

Authors:  Manel Esteller
Journal:  Nat Rev Genet       Date:  2011-11-18       Impact factor: 53.242

3.  Extending the phenotypes associated with DICER1 mutations.

Authors:  William D Foulkes; Amin Bahubeshi; Nancy Hamel; Barbara Pasini; Sofia Asioli; Gareth Baynam; Catherine S Choong; Adrian Charles; Richard P Frieder; Megan K Dishop; Nicole Graf; Mesiha Ekim; Dorothée Bouron-Dal Soglio; Jocelyne Arseneau; Robert H Young; Nelly Sabbaghian; Archana Srivastava; Marc D Tischkowitz; John R Priest
Journal:  Hum Mutat       Date:  2011-10-11       Impact factor: 4.878

4.  Overexpression of Dicer predicts poor survival in colorectal cancer.

Authors:  C Faber; D Horst; F Hlubek; T Kirchner
Journal:  Eur J Cancer       Date:  2011-02-21       Impact factor: 9.162

Review 5.  MicroRNA regulation by RNA-binding proteins and its implications for cancer.

Authors:  Marieke van Kouwenhove; Martijn Kedde; Reuven Agami
Journal:  Nat Rev Cancer       Date:  2011-08-05       Impact factor: 60.716

6.  Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma.

Authors:  Joana Heinzelmann; Brenda Henning; Jimsgene Sanjmyatav; Nicole Posorski; Thomas Steiner; Heiko Wunderlich; Mieczyslaw R Gajda; Kerstin Junker
Journal:  World J Urol       Date:  2011-01-13       Impact factor: 4.226

7.  microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma.

Authors:  Ruey-Jen Lin; You-Chin Lin; Jeremy Chen; Huan-Hsien Kuo; Yuan-Yan Chen; Mitchell B Diccianni; Wendy B London; Chih-Hao Chang; Alice L Yu
Journal:  Cancer Res       Date:  2010-08-30       Impact factor: 12.701

Review 8.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

9.  Dicer1 functions as a haploinsufficient tumor suppressor.

Authors:  Madhu S Kumar; Ryan E Pester; Cindy Y Chen; Keara Lane; Christine Chin; Jun Lu; David G Kirsch; Todd R Golub; Tyler Jacks
Journal:  Genes Dev       Date:  2009-11-10       Impact factor: 11.361

10.  Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma.

Authors:  Jeffrey K Mito; Richard F Riedel; Leslie Dodd; Guy Lahat; Alexander J Lazar; Rebecca D Dodd; Lars Stangenberg; William C Eward; Francis J Hornicek; Sam S Yoon; Brian E Brigman; Tyler Jacks; Dina Lev; Sayan Mukherjee; David G Kirsch
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more
  22 in total

1.  Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182.

Authors:  Mohit Sachdeva; Rebecca D Dodd; Zhiqing Huang; Carole Grenier; Yan Ma; Dina C Lev; Diana M Cardona; Susan K Murphy; David G Kirsch
Journal:  Cancer Lett       Date:  2015-08-24       Impact factor: 8.679

Review 2.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.

Authors:  Matthew Holderfield; Marian M Deuker; Frank McCormick; Martin McMahon
Journal:  Nat Rev Cancer       Date:  2014-07       Impact factor: 60.716

3.  TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.

Authors:  Anny Shai; David Dankort; Joseph Juan; Shon Green; Martin McMahon
Journal:  Cancer Res       Date:  2015-05-22       Impact factor: 12.701

4.  Algorithms for differentiating between images of heterogeneous tissue across fluorescence microscopes.

Authors:  Rhea Chitalia; Jenna Mueller; Henry L Fu; Melodi Javid Whitley; David G Kirsch; J Quincy Brown; Rebecca Willett; Nimmi Ramanujam
Journal:  Biomed Opt Express       Date:  2016-08-12       Impact factor: 3.732

5.  Methods to generate genetically engineered mouse models of soft tissue sarcoma.

Authors:  Rebecca D Dodd; Leonor Añó; Jordan M Blum; Zhizhong Li; David Van Mater; David G Kirsch
Journal:  Methods Mol Biol       Date:  2015

6.  A quantitative microscopic approach to predict local recurrence based on in vivo intraoperative imaging of sarcoma tumor margins.

Authors:  Jenna L Mueller; Henry L Fu; Jeffrey K Mito; Melodi J Whitley; Rhea Chitalia; Alaattin Erkanli; Leslie Dodd; Diana M Cardona; Joseph Geradts; Rebecca M Willett; David G Kirsch; Nimmi Ramanujam
Journal:  Int J Cancer       Date:  2015-06-03       Impact factor: 7.396

7.  Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer.

Authors:  Clare M Adams; Christine M Eischen
Journal:  Cancer Res       Date:  2014-05-19       Impact factor: 12.701

8.  MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes.

Authors:  Mohit Sachdeva; Jeffrey K Mito; Chang-Lung Lee; Minsi Zhang; Zhizhong Li; Rebecca D Dodd; David Cason; Lixia Luo; Yan Ma; David Van Mater; Rebecca Gladdy; Dina C Lev; Diana M Cardona; David G Kirsch
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

Review 9.  The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

Authors:  Xiyin Wang; Mircea Ivan; Shannon M Hawkins
Journal:  Gynecol Oncol       Date:  2017-08-31       Impact factor: 5.482

10.  miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer.

Authors:  Xiaoyan Liu; Lei Bi; Qin Wang; Mingxin Wen; Ce Li; Yidan Ren; Qinlian Jiao; Jian-Hua Mao; Chuanxin Wang; Guangwei Wei; Yunshan Wang
Journal:  Oncogene       Date:  2018-03-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.